Abu Lila AS - Search Results

1

Nano-Conversion of Ineffective Cephalosporins into Potent One against Resistant Clinical Uro-Pathogens via Gold Nanoparticles.

Rizvi SMD, Hussain T, Alshammari F, Sonbol H, Ahmad N, Faiyaz SSM, Kamal MA, Khafagy ES, Moin A, Abu Lila AS. Rizvi SMD, et al. Among authors: abu lila as. Nanomaterials (Basel). 2023 Jan 24;13(3):475. doi: 10.3390/nano13030475. Nanomaterials (Basel). 2023. PMID: 36770436 Free PMC article.

2

B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice.

Hashimoto Y, Abu Lila AS, Shimizu T, Ishida T, Kiwada H. Hashimoto Y, et al. Among authors: abu lila as. J Control Release. 2014 Jun 28;184:1-8. doi: 10.1016/j.jconrel.2014.04.003. Epub 2014 Apr 13. J Control Release. 2014. PMID: 24727075

3

Targeting anticancer drugs to tumor vasculature using cationic liposomes.

Abu Lila AS, Ishida T, Kiwada H. Abu Lila AS, et al. Pharm Res. 2010 Jul;27(7):1171-83. doi: 10.1007/s11095-010-0110-1. Epub 2010 Mar 24. Pharm Res. 2010. PMID: 20333455 Review.

4

The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.

Alaaeldin E, Abu Lila AS, Moriyoshi N, Sarhan HA, Ishida T, Khaled KA, Kiwada H. Alaaeldin E, et al. Among authors: abu lila as. Pharm Res. 2013 Sep;30(9):2344-54. doi: 10.1007/s11095-013-1078-4. Epub 2013 May 15. Pharm Res. 2013. PMID: 23673556

5

A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.

El Sayed MM, Shimizu T, Abu Lila AS, Elsadek NE, Emam SE, Alaaeldin E, Kamal A, Sarhan HA, Ando H, Ishima Y, Ishida T. El Sayed MM, et al. Among authors: abu lila as. Int J Pharm. 2022 Mar 5;615:121539. doi: 10.1016/j.ijpharm.2022.121539. Epub 2022 Feb 3. Int J Pharm. 2022. PMID: 35124114

6

Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism.

Elsadek NE, Emam SE, Abu Lila AS, Shimizu T, Ando H, Ishima Y, Ishida T. Elsadek NE, et al. Among authors: abu lila as. Biol Pharm Bull. 2020;43(9):1393-1397. doi: 10.1248/bpb.b20-00345. Biol Pharm Bull. 2020. PMID: 32879214 Free article.

7

Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.

Abu Lila AS, Matsumoto H, Doi Y, Nakamura H, Ishida T, Kiwada H. Abu Lila AS, et al. Eur J Pharm Biopharm. 2012 Aug;81(3):524-31. doi: 10.1016/j.ejpb.2012.04.010. Epub 2012 Apr 25. Eur J Pharm Biopharm. 2012. PMID: 22554766

8

Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.

Abu Lila AS, Nawata K, Shimizu T, Ishida T, Kiwada H. Abu Lila AS, et al. Int J Pharm. 2013 Nov 1;456(1):235-42. doi: 10.1016/j.ijpharm.2013.07.059. Epub 2013 Aug 5. Int J Pharm. 2013. PMID: 23928149

9

Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.

Abu Lila AS, Kato C, Fukushima M, Huang CL, Wada H, Ishida T. Abu Lila AS, et al. Int J Oncol. 2016 Apr;48(4):1399-407. doi: 10.3892/ijo.2016.3367. Epub 2016 Feb 1. Int J Oncol. 2016. PMID: 26847426

10

Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.

Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H. Abu-Lila A, et al. J Control Release. 2009 Feb 20;134(1):18-25. doi: 10.1016/j.jconrel.2008.10.018. Epub 2008 Nov 5. J Control Release. 2009. PMID: 19010364

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters